Clinical pharmacology of nucleoside analogues;Pharmacologie clinique des analogues de nucléosides

Bulletin du Cancer

Volumn 89, Issue SPEC. ISS., 2002, Pages

  Milano, Gérard ^a   Chamorey, Anne Laure ^a   Thyss, Antoine ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Clinical pharmacology; Nucleoside analogues

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; DRUG METABOLITE; FLUDARABINE; GEMCITABINE; NUCLEOSIDE ANALOG; URACIL ARABINOSIDE;

CELL LEVEL; CLINICAL PHARMACOLOGY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; HUMAN; NEUTROPENIA; PHARMACODYNAMICS; REVIEW;

ANTIMETABOLITES; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CYTARABINE; CYTIDINE DEAMINASE; DCMP DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; PHOSPHORYLATION; PRODRUGS; VIDARABINE;

EID: 0036696414     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Ellison RR for Acute Leukemia Cooperative Group B. Arabinosylcytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507-11.
2. Kremer WB. Cytrarabine. Ann Inter Med 1975; 82: 864.
3. Chabner BA. Cytidine analogues in cancer chemotherapy and biotherapy. Second edition, Chabner BA, Longo DL, Ed. Lippincott-Raven, Philadephia 1996; 213-33.
4. Chou TC, Hutchinson DJ, Schmid FA, Philips FS, Metabolism and selective effect of 1-b-D-arabinofuranosyl-cytosine in L1210 and host tissues in vivo. Cancer Res 1975; 35: 225-36.
5. Furth JJ, Cohen SS. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res 1968; 28: 2061-7.
6. Hande KR, Chabner BA. Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells. Cancer Res 1978; 38: 579-85.
7. Guide pratique de pharmacocinétique dinique en oncologie. Frison-Roche Edit, Paris 1997.
8. Ho DHW, Brown NS, Benvenuto J. Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system. Clin Pharmacol Ther 1977; 22: 371-4.
9. Damon LE, Plunkett W, Linker CA. Plasma and cerebrospinal fluid pharmacokinetics of 1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosyluracil following the repeated intravenous administration of high and intermediate dose of 1-b-D-arabinofuranosylcytosine. Cancer Res 1991; 51: 4141-5.
10. Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hr continuous infusion. Cancer Treat Rep 1986; 70: 1059-66.
11. Griffin JD, Spriggs D, Wisch JS, Kufe DW. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol 1985; 3: 982-91.
12. Kreis W, Chaudri F, Chan K, Allen S, Budman DR, Schulman P, et al. Pharmacokinetics of low dose 1-β-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Cancer Res 1985; 45: 6498-501.
13. Lihiemark JO, Punkett W, Dixon DO. Relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 1985; 45: 5952-7.
14. Fleming R, Capizzi R, Rosner GL. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol 1995; 36: 425-30.
15. Plunkett W, Lihiemark JO, Adams TM, Nowak B, Estey E, Kantarjan H, et al. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 1987; 47: 3005-11.
16. Preisler HD, Rustum Y, Priore RL. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Eur J Cancer Clin Oncol 1985; 21: 23-30.
17. Rustum Y, Riva C, Preisler H. Pharmacokinetic parameters of 1-β-D-arabinosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity and response of patients with acute non lymphocytic leukemia treated with conventional and high-dose ara-C. Sem Oncol 1987; 14: 141-8.
18. Delmer A, Marie JP, Thevenin D, Subeville AM, Zittoun R. Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity. Leuk Lymphoma 1993; 10: 67-71.
19. Kakihara T, Fukuda T, Tanaka A, Emura I, Kishi K, Asami K, et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of d CK gene in relapsed leukemia. Leuk Lymphoma 1998; 31: 405-9.
20. Kreis W, Lesser M, Budman DR, Artin Z, DeAngelis L, Baskind P, et al. Phenotypic analysis of 1-β-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemother Pharmacol 1992; 30: 126-30.
21. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998; 103: 1096-103.
22. Teng YS, Anderson JE, Giblet ER. Cytidine deaminase: a new genetic polymorphism demonstrated in human granulocytes. Ann J Hum Genet 1975; 27: 492-7.
23. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Sem Oncol 1995; 22: 3-10.
24. Ruiz van Haperen VWT. Biochemical pharmacology of gemcitabine. Thesis 1994. Vu University Press, Amsterdam.
25. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
26. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mami S, Hawkins M, et al. Phase I and pharmacokinetic trial of gemcitabine in patient with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18: 2780-7.
27. Van Moorsel CJA, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Annals Oncol 1999; 10: 441-8.
28. Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996; 38: 335-42.
29. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthader HG, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999; 10: 525-31.
30. Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K. Achievement of complete remission in refractory hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 2001; 19: 101-4.
31. Plunkett W, Gandhi V, Huang P, Roberston LE, Yang LY, Gregoire V, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Sem Oncol 1993; 20: 2-12.
32. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48: 329-34.
33. Johnson SA. Clinical pharmacokinetics of nucleoside analogues. Focus on haematological malignancies. Clin Pharamcokinet 2000; 39: 5-26.
34. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37.
35. Malspeis L, Gever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Sem Oncol 1990; 17 (suppl. 8): 18-32.
36. Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 1986; 17: 277-80.
37. Kemena A, Keating M, Plunkett W. Oral bioavailability of plasma fludarabine and fludarabine triphosphate in peripheral CLL cells. Onkologie 1991; 14: 83.
38. Danhauser L, Plinkett W, Keating M, Cabanillas F. 9-β-arabino furanosyl-2-fluoroademine 5′ monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 1986; 18: 145-52.
39. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1995; 1: 169-78.